Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Product Liability Law & StrategyColumns & DepartmentsLitigationLJN NewslettersProducts Liability

Case Notes

By ljnstaff | Law Journal Newsletters
April 02, 2017

Tylenol MDL Is Settled

A settlement was reached on Feb. 10 between McNeil Consumer Healthcare (a subsidiary of Johnson & Johnson) and more than 200 plaintiffs who claim liver damage from taking the drug maker's product, Tylenol. The defendant drug maker had been unsuccessful last summer in trying to block the testimony of one plaintiff's proposed expert witness, gastroenterologist and hepatologist Dr. Neil Kaplowitz, who was tapped to testify that Tylenol's active ingredient, Acetaminophen, can cause liver damage. U.S. District Judge Lawrence F. Stengel said of Dr. Kaplowitz at that time: “In rendering his general causation opinions, Dr. Kaplowitz considered the totality of the evidence and weighed the available information about acetaminophen-induced” by relying on “his own clinical experience, case reports, [U.S. Food and Drug Administration] documents including an analysis of the FDA's adverse event reports (AERs) database, published clinical studies and case series involving acetaminophen (including a study he coauthored in 2006), and animal studies.” The doctor was thus deemed qualified to offer his expert opinion at trial.

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

A Lawyer's System for Active Reading Image

Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.